NEW YORK - SABA: A recent study has highlighted an exciting new development in migraine treatment. Migraines, affecting billions globally, often bring debilitating headache pain that disrupts daily life.
The latest research reveals that the drug *ubrogepant*, marketed under the brand name *Uberlevi*, might offer a groundbreaking approach by preventing migraines before they fully develop.
The study, funded by the drug's developer AbbVie, explored how *ubrogepant* could be effective if administered at the onset of pre-migraine symptoms—such as sensitivity to light—before the severe headache pain begins.
Traditionally, *ubrogepant* is used to treat migraines once they have started, but this new research tests its efficacy in early intervention.
*Ubrogepant* targets a protein known as CGRP (calcitonin gene-related peptide), which is instrumental in the migraine process.
Neurologist Richard Lipton from Albert Einstein College of Medicine in New York City, who was involved in the study, highlights the potential benefit of addressing migraines at their earliest signs.
"Our findings suggest that *ubrogepant* may allow migraine sufferers to manage their condition more effectively, maintaining their daily routines with less discomfort and disruption," Lipton stated.
In the study, over 400 adults with a history of migraines participated. They were divided into two groups: one received ubrogepant at the onset of pre-migraine symptoms, while the other group received a placebo.
The results were promising: 65% of those who took ubrogepant reported minimal to no restriction from pain 24 hours later, compared to 48% in the placebo group.
Additionally, those on *ubrogepant* experienced faster relief, with many reporting significant improvement within just two hours.
Despite these encouraging outcomes, the study relied on self-reported data rather than objective clinical measurements, and the drug was not effective for every participant every time. Nonetheless, the results offer a hopeful new avenue for managing migraines more proactively.
Improving care at the first signs of a migraine could be crucial for better outcomes," Lipton concluded.
The research suggests that *ubrogepant* could significantly enhance the quality of life for those who suffer from migraines, helping them manage their condition more effectively and maintain their daily activities.
The latest research reveals that the drug *ubrogepant*, marketed under the brand name *Uberlevi*, might offer a groundbreaking approach by preventing migraines before they fully develop.
The study, funded by the drug's developer AbbVie, explored how *ubrogepant* could be effective if administered at the onset of pre-migraine symptoms—such as sensitivity to light—before the severe headache pain begins.
Traditionally, *ubrogepant* is used to treat migraines once they have started, but this new research tests its efficacy in early intervention.
*Ubrogepant* targets a protein known as CGRP (calcitonin gene-related peptide), which is instrumental in the migraine process.
Neurologist Richard Lipton from Albert Einstein College of Medicine in New York City, who was involved in the study, highlights the potential benefit of addressing migraines at their earliest signs.
"Our findings suggest that *ubrogepant* may allow migraine sufferers to manage their condition more effectively, maintaining their daily routines with less discomfort and disruption," Lipton stated.
In the study, over 400 adults with a history of migraines participated. They were divided into two groups: one received ubrogepant at the onset of pre-migraine symptoms, while the other group received a placebo.
The results were promising: 65% of those who took ubrogepant reported minimal to no restriction from pain 24 hours later, compared to 48% in the placebo group.
Additionally, those on *ubrogepant* experienced faster relief, with many reporting significant improvement within just two hours.
Despite these encouraging outcomes, the study relied on self-reported data rather than objective clinical measurements, and the drug was not effective for every participant every time. Nonetheless, the results offer a hopeful new avenue for managing migraines more proactively.
Improving care at the first signs of a migraine could be crucial for better outcomes," Lipton concluded.
The research suggests that *ubrogepant* could significantly enhance the quality of life for those who suffer from migraines, helping them manage their condition more effectively and maintain their daily activities.